ARK Invest’s Latest Moves: CoreWeave and Kratos Purchases Highlight February 27 Trading

Quick Summary

• ARK Invest acquired approximately $19.4M in CoreWeave stock following a 19% decline after the company’s Q4 earnings report
• The fund’s most significant transaction was a $23.2M acquisition of Kratos Defense & Security Solutions shares
• Teradyne holdings were reduced by $12.9M, extending ARK’s pattern of trimming this position
• ARK decreased its Rocket Lab stake despite the company exceeding earnings forecasts, with shares declining roughly 5%
• Additional moves included divesting Roku holdings and establishing a position in Generate Biomedicines

---

On Friday, February 27, Cathie Wood’s ARK Invest executed multiple strategic portfolio adjustments. The trading activity encompassed fresh investments and position reductions spanning technology, defense, and biotechnology sectors.

Kratos Defense & Security Solutions emerged as the day’s most substantial acquisition. ARK accumulated 252,169 shares valued at $23.2 million. The company specializes in unmanned aerial systems and autonomous defense technologies, aligning with ARK’s investment thesis centered on robotics and automation.

The second-largest acquisition involved CoreWeave, a provider of AI-focused cloud infrastructure. ARK secured 198,980 shares totaling approximately $19.4 million, distributed between its ARKK and ARKW exchange-traded funds.

CoreWeave, Inc. Class A Common Stock, CRWV

ARK’s CoreWeave purchase occurred during a session where the stock declined 19%. The downturn followed fourth-quarter earnings that demonstrated robust revenue growth but revealed expanding losses and capital expenditures that exceeded market expectations.

By purchasing shares during the selloff, ARK appears to interpret the market reaction as temporary volatility rather than fundamental business deterioration. CoreWeave operates in the AI computing infrastructure space, which has experienced substantial demand expansion.

CoreWeave maintains a Moderate Buy rating among Wall Street analysts. With eleven Buy ratings and eight Hold ratings, the consensus price target of $114.18 suggests potential upside of approximately 43.5% from current trading levels.

ARK Scales Back Teradyne and Rocket Lab Holdings

Regarding portfolio reductions, ARK divested 38,773 Teradyne shares valued at $12.9 million across several ETFs. Teradyne manufactures semiconductor testing systems and industrial automation equipment. This transaction continues ARK’s recent pattern of decreasing its Teradyne exposure.

ARK also liquidated 46,921 shares of Rocket Lab valued at approximately $3.4 million. The space technology company had recently announced quarterly performance that surpassed both earnings and revenue projections, yet shares declined roughly 5% on Friday.

Rocket Lab disclosed robust launch operations and an expanding order backlog. Nevertheless, the inaugural launch of its larger Neutron rocket was delayed until late 2026, potentially contributing to investor disappointment.

Additional Portfolio Adjustments in Biotech and Technology

ARK disposed of 46,389 shares of Roku valued at $4.3 million from its ARKK fund. The rationale for this divestment was not publicly disclosed.

Within the biotechnology sector, ARK acquired 459,525 shares of Generate Biomedicines valued at $7.4 million via its ARKG fund. Simultaneously, the fund sold 39,423 shares of Ionis Pharmaceuticals for $3.2 million.

ARK liquidated 10,590 Deere & Co shares for $6.6 million and reduced its Guardant Health position by 27,334 shares valued at $2.7 million.

Minor transactions included a reduction of 205,211 PagerDuty shares for $1.5 million and an acquisition of 14,097 Brera Holdings shares valued at approximately $15,600.

The CoreWeave and Kratos acquisitions represented ARK’s two most significant individual transactions on February 27, with combined value exceeding $42 million.

The post ARK Invest’s Latest Moves: CoreWeave and Kratos Purchases Highlight February 27 Trading appeared first on Blockonomi.